Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxidex for Marginal Corneal Infiltrates
NCT00579020Phase 2Terminated
- Sponsor
- Alcon Inc.
- Start
- Dec 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of moxifloxacin + dexamethasone in Marginal corneal infiltrates, sponsored by Alcon Inc. Primary endpoint: Percentage of patients with resolution of all corneal stromal infiltrate(s) in study eye at Day 10. Started Dec 2007; status: terminated.
02
Drugs
moxifloxacin + dexamethasone
03
Conditions
Marginal corneal infiltrates
Beyond the preview
Go deeper on NCT00579020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00579020.